You are here

  • Home
  • Archive
  • Volume 15, Issue Suppl 3
  • First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

Citation Tools

Article menu
Download PDFPDF
Articles
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
KRISTENSEN GB, VERGOTE I, STUART G, et al
First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB–IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival
International Journal of Gynecologic Cancer 2005;15:221.